Senomorphics
Senomorphics has been studied in 269 papers since 2018: 1 observational study in people, 5 in cells, 261 reviews; 135 in the past year. It has not reached trials in people. The newest paper, Nov 20, 2026: “Targeting accelerated kidney ageing in chronic kidney disease: from senolytics to Klotho therapeutics”.
InterventionPreclinical
269 papers study it47 findingsUpdated
Research on it is growing 96% faster than aging research as a whole: 186 papers in the latest year counted
28 new papers in 30 daysSee all 269 papers on senomorphics
At a glance
Senomorphics decrease cellular senescence in human cells, a result independent labs reproduce, but a study reports increased senescence after pretreatment of well-decidualized cells. Reviews describe suppression of the senescence-associated secretory phenotype; a study in doxorubicin-treated engineered heart tissues reports no clear cardiac-function effect. Some papers declare company ties.
47 findings in 44 papers from 2019 to 2026, 17 of them since April 2026
The findings reach cells, none yet in people; independent labs found the same change in cells. 5 independent labs in 5 countries.
1 of its findings points the other way.
- 5 independent labs in 5 countries
- 1 finding against
- Funders: Avicenna Research Institute and others
- 4 of 9 findings with company ties
- Humans1
- Cells5
- In silico2
What did studies of senomorphics find?
13Studies of senomorphics measured 13 outcomes; the most studied are senescence-associated secretory phenotype (SASP) (28 studies), cellular senescence (3) and osteoarthritis (2).
Senescence-associated secretory phenotype (SASP)
downin reviews27downin humans1
28 studies
Senescence-associated secretory phenotype (SASP)
downin reviews27downin humans1
Senomorphics decrease senescence-associated secretory phenotype (SASP).
Review
Senomorphics inhibit senescence-associated secretory phenotype (SASP).
Review
Senomorphics decrease senescence-associated secretory phenotype (SASP).
Review
Senomorphics inhibit senescence-associated secretory phenotype (SASP).
Review
Senomorphics inhibit senescence-associated secretory phenotype (SASP).
Review
Senomorphics inhibit senescence-associated secretory phenotype (SASP).
Review
Senomorphics inhibit senescence-associated secretory phenotype (SASP).
Review
Senomorphics inhibit senescence-associated secretory phenotype (SASP) in humans.
Reviewskin
Senomorphics decrease senescence-associated secretory phenotype (SASP).
Review
Senomorphics inhibit senescence-associated secretory phenotype (SASP).
Review
All 28Fewer
Cellular senescence
downin human cells3upin human cells1
3 studies
Cellular senescence
downin human cells3upin human cells1
Senomorphics decrease cellular senescence in human cells (UV-induced senescence in XP-derived melanocytes).
CellsUV-induced senescence in XP-derived melanocytesmelanocyte
Senomorphics increase cellular senescence in human cells (pretreatment in well-decidualized cells).
Cellspretreatment in well-decidualized cells
Senomorphics decrease cellular senescence in human cells (pretreatment in poorly-decidualized cells).
Cellspretreatment in poorly-decidualized cells
Senomorphics decrease cellular senescence in doxorubicin-treated dynamic engineered heart tissues.
Cellsin doxorubicin-treated dynamic engineered heart tissuesheart
Osteoarthritis
downin mice1downin reviews1
2 studies
Osteoarthritis
downin mice1downin reviews1
Senomorphics protect against osteoarthritis (preclinical models).
Reviewpreclinical models
Senomorphics decrease osteoarthritis in murine models of OA.
Reviewin murine models of OA
Decidualization
upin human cells2
2 studies
Decidualization
upin human cells2
Senomorphics improve decidualization in senescent endometrial stromal cells; senomorphics rapamycin and metformin.
Cellsin senescent endometrial stromal cells; senomorphics rapamycin and metformin
Senomorphics improve decidualization in senescent ESCs.
Cellsin senescent ESCsendometrium
SASP gene expression
downin human cells1
1 study
SASP gene expression
downin human cells1
Senomorphics decrease SASP gene expression in human cells (UV-induced senescence in XP-derived melanocytes).
CellsUV-induced senescence in XP-derived melanocytesmelanocyte
Macrophage functions
upin human cells1
1 study
Macrophage functions
upin human cells1
Senomorphics improve macrophage functions in human cells (senomorphic treatment of senescent VSMCs before conditioned media transfer).
Cellssenomorphic treatment of senescent VSMCs before conditioned media transfer
Secretion of senescence-promoting mediators
downin reviews1
1 study
Secretion of senescence-promoting mediators
downin reviews1
Senomorphics inhibit secretion of senescence-promoting mediators.
Review
Disease progression
downin Rodentia1
1 study
Disease progression
downin Rodentia1
Senomorphics decrease disease progression in Rodentia.
Review
Cardiac function
no changein human cells1
1 study
Cardiac function
no changein human cells1
Senomorphics showed no clear effect on cardiac function in doxorubicin-treated dynamic engineered heart tissues.
Cellsin doxorubicin-treated dynamic engineered heart tissuesheart
Intervertebral disc degeneration
downin reviews1
1 study
Intervertebral disc degeneration
downin reviews1
Senomorphics protect against intervertebral disc degeneration (degenerative diseases including IVDD).
Reviewdegenerative diseases including IVDD
All 13Fewer
What is senomorphics linked with?
2Studies link senomorphics with 2 measures: senescence-associated secretory phenotype (SASP) and senolytics.
Senescence-associated secretory phenotype (SASP)
mixedin reviews1
1 study
Senescence-associated secretory phenotype (SASP)
mixedin reviews1
Senomorphics are associated with senescence-associated secretory phenotype (SASP) (without removing senescent cells).
Reviewwithout removing senescent cellssenescent cells
Senolytics
no changein silico1
1 study
Senolytics
no changein silico1
Senolytics are associated with senomorphics in silico (comparison of physicochemical, structural and pharmacological properties).
In silicocomparison of physicochemical, structural and pharmacological propertiesn = 84
How this record changed
Summary written from the findings.